Neurocrine Biosciences (NBIX) EBT Growth (1y) (2011 - 2026)
Neurocrine Biosciences (NBIX) EBT Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | -324.14% |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | -5.04% |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | -1.93% |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | -8.74% |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 70.52% |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 1.69% |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 124.00% |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Alkermes | 8.02 Bn | 7.37 Bn | 397.90 Mn | -101.79% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.69% |
| Mar 31, 2026 | 1,578.91% |
| Dec 31, 2025 | 47.23% |
| Sep 30, 2025 | 53.34% |
| Jun 30, 2025 | 61.76% |
| Mar 31, 2025 | -57.39% |
| Dec 31, 2024 | -17.96% |
| Sep 30, 2024 | 64.62% |
| Jun 30, 2024 | -18.91% |
| Mar 31, 2024 | 133.40% |
| Dec 31, 2023 | 68.11% |
| Sep 30, 2023 | 18.08% |
| Jun 30, 2023 | 621.89% |
| Mar 31, 2023 | -582.71% |
| Dec 31, 2022 | 954.35% |
| Sep 30, 2022 | 220.98% |
| Jun 30, 2022 | -140.52% |
| Mar 31, 2022 | -21.32% |
| Dec 31, 2021 | -133.09% |
| Sep 30, 2021 | 153.42% |